NAVBQ.US Navidea Biopharmaceuticals Inc.
- Market cap
- USD 10.0K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is NAVBQ.US undervalued?
Graham numberThe Graham number of Navidea Biopharmaceuticals Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Navidea Biopharmaceuticals Inc. fundamental analysis
No fundamental analysis for Navidea Biopharmaceuticals Inc. yet.
Navidea Biopharmaceuticals Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emiss…
Full company profileNavidea Biopharmaceuticals Inc. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Navidea Biopharmaceuticals Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.13M | 6.27M | 13.2M | 4.97M | 1.81M | 323K | 26.6K | 915K | 532K | 65.7K | - |
| Gross Profit | 798K | 4.20M | 11.5M | 4.41M | 1.81M | 226K | 20.0K | 914K | 333K | -170K | -145K |
| Operating Income | -38.4M | -27.0M | -17.3M | -10.1M | -13.9M | -10.8M | -11.0M | -10.7M | -12.1M | -14.1M | -9.31M |
| EBITDA | -38.0M | -31.5M | -21.3M | -6.87M | -17.4M | -15.9M | -10.8M | -10.6M | -11.6M | -14.0M | -7.59M |
| Net Income | -42.7M | -35.7M | -27.6M | -14.3M | 74.9M | -16.1M | -10.9M | -10.7M | -11.7M | -15.2M | 3.07M |
| EPS | -7.01 | -4.80 | -3.65 | -1.84 | 9.03 | -1.89 | -0.76 | -0.45 | -0.40 | -0.49 | 0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 40.3M | 11.9M | 15.0M | 12.5M | 20.8M | 7.01M | 4.15M | 7.76M | 6.64M | 4.37M | 5.70M |
| Total Liabilities | 44.3M | 41.7M | 68.8M | 80.1M | 8.73M | 4.61M | 5.03M | 5.71M | 6.02M | 12.5M | 8.68M |
| Shareholders' Equity | -4.01M | -29.8M | -54.3M | -68.1M | 11.4M | 1.74M | -1.61M | 1.32M | -107K | -8.44M | -3.27M |
| Cash & Short-term Investments | 32.9M | 5.48M | 7.17M | 1.54M | 4.59M | 4.28M | 1.05M | 2.67M | 4.23M | 2.00M | 3.86M |
| Total Debt | 27.7M | 33.9M | 61.1M | 61.6M | 2.35M | 316K | 1.07M | 1.34M | 749K | 2.44M | 1.26M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -35.6M | -29.1M | -19.1M | 3.56M | 59.1M | 4.28M | -9.35M | -8.17M | -10.2M | -8.99M | 193K |
| Capital Expenditure | 1.29M | 1.19M | 66.1K | 1.85K | 33.7K | 46.2K | 56.7K | 414K | 329K | 390K | 162K |
| Free Cash Flow | -36.9M | -30.3M | -19.1M | 3.55M | 59.0M | 4.23M | -9.41M | -8.59M | -10.5M | -9.38M | -9.87M |
| Ratios | |||||||||||
| ROE | - | - | - | - | 658.6% | -925.7% | - | -815.0% | - | - | - |
| ROA | -105.9% | -299.7% | -184.2% | -114.8% | 360.6% | -230.1% | -263.7% | -138.2% | -176.5% | -347.2% | 53.8% |
| Net Profit Margin | -3,776.6% | -569.4% | -208.0% | -287.8% | 4,139.7% | -5,000.1% | -41,120.9% | -1,171.8% | -2,207.1% | -23,117.6% | - |
| Debt to Equity | - | - | - | - | 0.21x | 0.18x | - | 1.02x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Navidea Biopharmaceuticals Inc. dividends
Navidea Biopharmaceuticals Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Apr 26, 2019.
Who owns Navidea Biopharmaceuticals Inc.
Ownership data of Navidea Biopharmaceuticals Inc. is not available yet.
Navidea Biopharmaceuticals Inc. company profile
- Company name
- Navidea Biopharmaceuticals Inc.
- Ticker
- NAVBQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- 4995 Bradenton Avenue, Dublin, OH, United States, 43017-3552
- Phone
- 614 793 7500
- Website
- navidea.com
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio. On October 1, 2025, Navidea Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Navidea Biopharmaceuticals Inc. management
1- Mr. Craig A. Dais CPACFO & Principal Accounting Officer · born 1967